The CIBIC-plus is not a single instrument and is not a standardized instrument like the ADAS-cog. Table 1. There is no evidence that Donepezil alters the course of the underlying dementing process.The elimination half life of Donepezil is about 70 hours, and the mean apparent plasma clearance (Cl/F) is 0.13 to 0.19 L/hr/kg. If you would like more information, talk with the patient's doctor. Time-course of the Change from Baseline in ADAS-cog Score for Patients Completing 24 Weeks of Treatment.The curves demonstrate that both patients assigned to placebo and Donepezil hydrochloride have a wide range of responses, but that the active treatment groups are more likely to show greater improvements. Drug information contained herein may be time sensitive. Formal pharmacokinetic studies evaluated the potential of Donepezil hydrochloride for interaction with theophylline, cimetidine, warfarin, digoxin, and ketoconazole. Do not give Donepezil hydrochloride tablets to people other than people, even if they have the same symptoms or conditions. Cumulative Percentage of Patients Completing 24 Weeks of Double-blind Treatment with Specified Changes from Baseline ADAS-cog Scores. These adverse reactions were often transient, resolving during continued Donepezil hydrochloride treatment without the need for dose modification.Table 4 lists adverse reactions that occurred in at least 2% of patients in pooled placebo-controlled trials who received Donepezil hydrochloride 5 mg or 10 mg and for which the rate of occurrence was greater for patients treated with Donepezil hydrochloride than with placebo.Abdominal pain, agitation, aggression, cholecystitis, confusion, convulsions, hallucinations, heart block (all types), hemolytic anemia, hepatitis, hyponatremia, neuroleptic malignant syndrome, pancreatitis, rash, rhabdomyolysis, QTc prolongation, and torsade de pointes.There are no adequate data on the developmental risks associated with the use of Donepezil hydrochloride in pregnant women. Adverse in Pooled Controlled Clinical Trials in Severe Alzheimer's DiseaseEffect of Donepezil Hydrochloride on the Metabolism of Other Drugs Effect of Other Drugs on the Metabolism of Donepezil HydrochlorideWho should not take Donepezil hydrochloride tablets?What should I tell the doctor before the patient taking Donepezil hydrochloride tablets?Tell the doctor about all of the patient's present or past health problems and conditions.Tell the doctor about all the medicines the patient takes,How should the patient take Donepezil hydrochlorideWhat are the possible side effects of Donepezil hydrochloride tablets?Donepezil hydrochloride tablets may cause the following serious side effects:The most common side effects of Donepezil hydrochloride tablets are:These side effects may get better after the patient takes Donepezil hydrochloride tablets for a while. Frequency Distribution of CIBIC-plus Scores at Week 24.In a study of 15 weeks duration, patients were randomized to receive single daily doses of placebo or either 5 mg/day or 10 mg/day of Donepezil hydrochloride for 12 weeks, followed by a 3-week placebo washout period. Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. For more information, call Graviti Pharmaceuticals Inc., at 1-855-298-4506.The brand names listed are trademarks of their respective owners and are not trademark of the Graviti Pharmaceuticals Private Limited.PHARMACIST: Dispense the accompanying Patient Information Leaflet to each patient.PHARMACIST: Dispense the accompanying Patient Information Leaflet to each patient.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records.